Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bifeprunox in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main inclusion criteria~* The subject has a primary diagnosis of schizophrenia~* The subject experiences clinically significant symptoms~* The subject's medication remained stable for 8 weeks prior to screening~* The subject is currently in the post-acute maintenance phase of his/her disease~Exclusion Criteria:~Main exclusion criteria~* The subject is at significant risk of suicide~* The subject is treatment resistant~* The subject has experienced an acute exacerbation within 8 weeks prior screening~* The subject is unlikely to comply with the protocol~* The subject has a current diagnosis or a history of substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bifeprunox (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Quetiapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).